EXPANSION OF
EUROPEAN PATENT
GRANTS

RELEASE DATE: June 15 2021

Cancelex’s confirms notification of grant intention in Europe for any Smad3 inhibitor products, with further patent
coverage as expanded to the following: liver cancer, cancer of the lymph nodes, brain cancer, kidney cancer, colon cancer, gastric cancer, & bone cancer.

Expanded coverage follows our earlier European grant of rights for any Smad3 inhibitor products addressing lung cancer and melanoma. Recent patent coverage adds to our library of board patents already granted in China and Hong Kong secured against any Smad3 inhibitor products on any cancers.
Moexa’s patent library is a further commercial step to support IND approval in anticipation of clinical trials.

Parties interested in investments or further collaborations may contact us for more information. www.cancelex.com

info@moexa.com